Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2006
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Journey Medical Corporation reported total revenues of $18.5 million for the second quarter of 2026, a 23% increase from $15.0 million in the prior-year quarter. - Emrosi generated $8.1 million in revenue during the quarter, with total prescriptions rising to approximately 36,000, up from 30,000 in Q1 2026 and 27,000 in Q4 2025. - GAAP net loss narrowed to $0.3 million, or $(0.01) per share, compared to a net loss of $3.8 million, or $(0.16) per share, in the second quarter of 2025. - The company held $25.6 million in cash and cash equivalents as of June 30, 2026, positioning it to advance its dermatology strategy toward profitability.
- A Complete Response Letter (CRL) is the FDA's formal notice that a drug application cannot be approved in its current form, citing deficiencies in safety, efficacy, manufacturing, or labeling. - CRLs can trigger severe market reactions, with single-day stock declines ranging from 2% (AbbVie) to 75% (Aldeyra Therapeutics), depending on the nature and severity of the deficiencies. - Companies can pursue Class 1 resubmissions for minor fixes (approximately two-month review) or Class 2 resubmissions for substantial changes (approximately six-month review), with successful resubmissions enabling significant stock recoveries. - Fortress Biotech's CUTX-101 and Capricor Therapeutics' deramiocel demonstrate that CRLs are not terminal, as both programs advanced toward approval following resubmission.
- Journey Medical Corporation announced positive Phase 1 clinical trial results for Emrosi (low-dose minocycline) published in the Journal of Drugs in Dermatology, demonstrating the treatment met all three primary objectives with no significant safety issues. - The 16-week study of 60 healthy adults showed no detectable effects on skin, gastrointestinal tract, or vaginal microflora, with no development of antibiotic resistance to minocycline. - Emrosi is FDA-approved for treating inflammatory lesions of rosacea in adults, a condition affecting over 16 million Americans and 415 million people worldwide. - The results support Emrosi's potential for long-term use as a therapeutic option for moderate-to-severe rosacea without meaningfully disrupting normal microbiota.
- Fortress Biotech achieved a 20.5% increase in net revenue to $17.6 million in Q3 2025, driven by strong performance from its dermatology products portfolio. - The company completed strategic exits with Sun Pharma acquiring Checkpoint Therapeutics for ~$28 million upfront to Fortress, plus potential additional payments and royalties. - Dotinurad, a next-generation URAT1 inhibitor for gout treatment, advanced into two Phase 3 trials following Crystalys Therapeutics' $205 million Series A financing. - Journey Medical's rosacea treatment Emrosi demonstrated statistical superiority over existing therapies in pooled Phase 3 analysis, with expanded payer coverage reaching over 100 million lives.
- Journey Medical's Emrosi (DFD-29) achieved 62.7% IGA treatment success compared to 39.0% for Oracea and 28.2% for placebo in combined Phase 3 trials (p<0.001). - The modified-release minocycline formulation reduced inflammatory lesions by 19.2 on average versus 14.8 for Oracea and 11.3 for placebo over 16 weeks. - The drug demonstrated a favorable safety profile with no major safety issues or serious adverse events related to the study drug in 653 patients. - Results were presented at the 2025 Fall Clinical Dermatology Conference, reinforcing Emrosi's potential as a standard of care for rosacea treatment.
- Fortress Biotech shares plummeted over 30% after the FDA issued a Complete Response Letter for CUTX-101, citing manufacturing facility deficiencies rather than safety or efficacy concerns. - The investigational copper histidinate treatment for pediatric Menkes disease had received Priority Review status and demonstrated significant improvement in overall survival for early-treated patients. - Sentynl Therapeutics, which assumed development responsibilities in December 2023, plans to address the current Good Manufacturing Practice issues and pursue prompt resubmission. - Despite the setback, Cyprium Therapeutics remains eligible for a Rare Pediatric Disease Priority Review Voucher and up to $129 million in milestones upon eventual approval.
- The FDA issued a Complete Response Letter for CUTX-101, a potential treatment for Menkes disease, citing manufacturing facility deficiencies but no concerns about the drug's safety or efficacy data. - CUTX-101 demonstrated significant improvement in overall survival for Menkes disease patients who received early treatment, supporting its Priority Review designation from the FDA. - Sentynl Therapeutics, which assumed development responsibility in 2023, plans to address the manufacturing issues and resubmit the application promptly. - Menkes disease affects between 1 in 8,664 to 1 in 34,810 live male births and currently has no FDA-approved treatment options.
- DelveInsight's 2025 assessment reveals 15+ companies are developing over 20 cytomegalovirus (CMV) infection treatment therapies across various clinical development phases. - Recent clinical milestones include Kamada's post-marketing research initiative for CYTOGAM, ACTG's encouraging HIV-CMV study results, and Fortress Biotech's Phase 2 trial initiation for Triplex vaccine. - The CMV pipeline encompasses diverse therapeutic approaches including mRNA vaccines, T-cell therapies, immune globulins, and antiviral compounds from companies like Moderna, Merck Sharp & Dohme, and Chimerix. - Market growth is driven by increasing CMV prevalence and research activities, though high treatment costs and healthcare infrastructure limitations present ongoing challenges.
- Fortress Biotech secured FDA approvals for two key products in Q4 2024: Emrosi for inflammatory lesions of rosacea and UNLOXCYT for advanced cutaneous squamous cell carcinoma, with commercial launch of Emrosi already underway. - Subsidiary Checkpoint Therapeutics is being acquired by Sun Pharma in a deal valued at $4.10 per share plus potential CVR of $0.70, expected to generate approximately $28 million for Fortress plus a 2.5% royalty on UNLOXCYT sales. - FDA accepted New Drug Application for CUTX-101 for priority review with PDUFA date of September 30, 2025, potentially qualifying for a valuable Priority Review Voucher upon approval.
- Fortress Biotech and Partex NV have announced a strategic collaboration leveraging Partex's proprietary AI platform to identify and evaluate biopharmaceutical compounds for potential acquisition or licensing. - The partnership aims to expedite target identification, indication expansion, and molecular profiling, ultimately accelerating the process of bringing innovative therapeutics to market more efficiently. - Fortress Biotech, with seven marketed products and over 20 programs in development, expects this AI-driven approach to enhance their business model of acquiring and advancing assets to create long-term shareholder value.
